The clinical outcomes of COVID-19 critically ill patients co-infected with other respiratory viruses: a multicenter, cohort study.
COVID19
Coinfection
Coronavirus disease
Critically ill
MV duration
Mortality
Outcomes
Respiratory viruses
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
06 Feb 2023
06 Feb 2023
Historique:
received:
10
07
2022
accepted:
17
01
2023
entrez:
7
2
2023
pubmed:
8
2
2023
medline:
9
2
2023
Statut:
epublish
Résumé
Previous studies have shown that non-critically ill COVID-19 patients co-infected with other respiratory viruses have poor clinical outcomes. However, limited studies focused on this co-infections in critically ill patients. This study aims to evaluate the clinical outcomes of critically ill patients infected with COVID-19 and co-infected by other respiratory viruses. A multicenter retrospective cohort study was conducted for all adult patients with COVID-19 who were hospitalized in the ICUs between March, 2020 and July, 2021. Eligible patients were sub-categorized into two groups based on simultaneous co-infection with other respiratory viruses throughout their ICU stay. Influenza A or B, Human Adenovirus (AdV), Human Coronavirus (i.e., 229E, HKU1, NL63, or OC43), Human Metapneumovirus, Human Rhinovirus/Enterovirus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), Parainfluenza virus, and Respiratory Syncytial Virus (RSV) were among the respiratory viral infections screened. Patients were followed until discharge from the hospital or in-hospital death. A total of 836 patients were included in the final analysis. Eleven patients (1.3%) were infected concomitantly with other respiratory viruses. Rhinovirus/Enterovirus (38.5%) was the most commonly reported co-infection. No difference was observed between the two groups regarding the 30-day mortality (HR 0.39, 95% CI 0.13, 1.20; p = 0.10). The in-hospital mortality was significantly lower among co-infected patients with other respiratory viruses compared with patients who were infected with COVID-19 alone (HR 0.32 95% CI 0.10, 0.97; p = 0.04). Patients concomitantly infected with other respiratory viruses had longer median mechanical ventilation (MV) duration and hospital length of stay (LOS). Critically ill patients with COVID-19 who were concomitantly infected with other respiratory viruses had comparable 30-day mortality to those not concomitantly infected. Further proactive testing and care may be required in the case of co-infection with respiratory viruses and COVID-19. The results of our study need to be confirmed by larger studies.
Sections du résumé
BACKGROUND
BACKGROUND
Previous studies have shown that non-critically ill COVID-19 patients co-infected with other respiratory viruses have poor clinical outcomes. However, limited studies focused on this co-infections in critically ill patients. This study aims to evaluate the clinical outcomes of critically ill patients infected with COVID-19 and co-infected by other respiratory viruses.
METHODS
METHODS
A multicenter retrospective cohort study was conducted for all adult patients with COVID-19 who were hospitalized in the ICUs between March, 2020 and July, 2021. Eligible patients were sub-categorized into two groups based on simultaneous co-infection with other respiratory viruses throughout their ICU stay. Influenza A or B, Human Adenovirus (AdV), Human Coronavirus (i.e., 229E, HKU1, NL63, or OC43), Human Metapneumovirus, Human Rhinovirus/Enterovirus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), Parainfluenza virus, and Respiratory Syncytial Virus (RSV) were among the respiratory viral infections screened. Patients were followed until discharge from the hospital or in-hospital death.
RESULTS
RESULTS
A total of 836 patients were included in the final analysis. Eleven patients (1.3%) were infected concomitantly with other respiratory viruses. Rhinovirus/Enterovirus (38.5%) was the most commonly reported co-infection. No difference was observed between the two groups regarding the 30-day mortality (HR 0.39, 95% CI 0.13, 1.20; p = 0.10). The in-hospital mortality was significantly lower among co-infected patients with other respiratory viruses compared with patients who were infected with COVID-19 alone (HR 0.32 95% CI 0.10, 0.97; p = 0.04). Patients concomitantly infected with other respiratory viruses had longer median mechanical ventilation (MV) duration and hospital length of stay (LOS).
CONCLUSION
CONCLUSIONS
Critically ill patients with COVID-19 who were concomitantly infected with other respiratory viruses had comparable 30-day mortality to those not concomitantly infected. Further proactive testing and care may be required in the case of co-infection with respiratory viruses and COVID-19. The results of our study need to be confirmed by larger studies.
Identifiants
pubmed: 36747136
doi: 10.1186/s12879-023-08010-8
pii: 10.1186/s12879-023-08010-8
pmc: PMC9901824
doi:
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
75Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2023. The Author(s).
Références
Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20. https://doi.org/10.1056/NEJMoa2002032 .
doi: 10.1056/NEJMoa2002032
pubmed: 32109013
Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect. 2020;81(2):266–75.
doi: 10.1016/j.jinf.2020.05.046
pubmed: 32473235
pmcid: 7255350
Malekifar P, Pakzad R, Shahbahrami R, Zandi M, Jafarpour A, Rezayat SA, et al. Viral coinfection among COVID-19 patient groups: an update systematic review and meta-analysis. Biomed Res Int. 2021;2021.
Swets MC, Russell CD, Harrison EM, Docherty AB, Lone N, Girvan M, et al. SARS-CoV-2 co-infection with influenza viruses, respiratory syncytial virus, or adenoviruses. Lancet. 2022;399(10334):1463–4.
doi: 10.1016/S0140-6736(22)00383-X
pubmed: 35344735
pmcid: 8956294
Alosaimi B, Naeem A, Hamed ME, Alkadi HS, Alanazi T, Al Rehily SS, et al. Influenza co-infection associated with severity and mortality in COVID-19 patients. Virol J. 2021;18(1):1–9. https://doi.org/10.1186/s12985-021-01594-0 .
doi: 10.1186/s12985-021-01594-0
Musuuza JS, Watson L, Parmasad V, Putman-Buehler N, Christensen L, Safdar N. Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: a systematic review and meta-analysis. PLoS ONE. 2021;16(5): e0251170. https://doi.org/10.1371/journal.pone.0251170 .
doi: 10.1371/journal.pone.0251170
pubmed: 33956882
pmcid: 8101968
Ma S, Lai X, Chen Z, Tu S, Qin K. Clinical characteristics of critically ill patients co-infected with SARS-CoV-2 and the influenza virus in Wuhan, China. Int J Infect Dis. 2020;96:683–7.
doi: 10.1016/j.ijid.2020.05.068
pubmed: 32470606
pmcid: 7250072
Sreenath K, Batra P, Vinayaraj E V., Bhatia R, SaiKiran K, Singh V, et al. Coinfections with other respiratory pathogens among patients with COVID-19. Microbiol Spectr. 2021;9(1).
Zoran MA, Savastru RS, Savastru DM, Tautan MN. Assessing the relationship between surface levels of PM2.5 and PM10 particulate matter impact on COVID-19 in Milan, Italy. Sci Total Environ. 2020;738.
Lansbury L, Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS. Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst Rev. 2019;2(6): 010406.
Lansbury LE, Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS. Corticosteroids as adjunctive therapy in the treatment of influenza: an updated cochrane systematic review and meta-analysis. Crit Care Med. 2020;48(2):E98-106.
doi: 10.1097/CCM.0000000000004093
pubmed: 31939808
Silva DL, Lima CM, Magalhães VCR, Baltazar LM, Peres NTA, Caligiorne RB, et al. Fungal and bacterial co-infections increase mortality of severely ill COVID-19 patients. J Hosp Infect. 2021;113:145–54.
doi: 10.1016/j.jhin.2021.04.001
pubmed: 33852950
pmcid: 8056850
Chekuri S, Szymczak WA, Goldstein DY, Nori P, Marrero Rolon R, Spund B, et al. SARS-CoV-2 co-infection with additional respiratory virus does not predict severe disease: a retrospective cohort study. J Antimicrob Chemother. 2021;76(Supplement_3):III12–9.
doi: 10.1093/jac/dkab244
pubmed: 34555160
Alqahtani A, Alamer E, Mir M, Alasmari A, Alshahrani MM, Asiri M, et al. Bacterial coinfections increase mortality of severely Ill COVID-19 patients in Saudi Arabia. Int J Environ Res Public Health. 2022;19(4).
Kaushal K, Kaur H, Sarma P, et al. Serum ferritin as a predictive biomarker in COVID-19. A systematic review, meta-analysis and meta-regression analysis. J Crit Care. 2022;67:172–81. https://doi.org/10.1016/j.jcrc.2021.09.023 .
doi: 10.1016/j.jcrc.2021.09.023
pubmed: 34808527
Djaharuddin I, Munawwarah S, Nurulita A, Ilyas M, Tabri NA, Lihawa N. Comorbidities and mortality in COVID-19 patients. Gac Sanit. 2021;35(Suppl 2):S530–2.
doi: 10.1016/j.gaceta.2021.10.085
pubmed: 34929892
pmcid: 8677356
Griffiths EC, Pedersen AB, Fenton A, Petchey OL. The nature and consequences of co-infection in humans. J Infect. 2011;63(3):200–6.
doi: 10.1016/j.jinf.2011.06.005
pubmed: 21704071
pmcid: 3430964
Echenique IA, Chan PA, Chapin KC, Andrea SB, Fava JL, Mermel LA. Clinical characteristics and outcomes in hospitalized patients with respiratory viral co-infection during the 2009 H1N1 influenza pandemic. PLoS ONE. 2013;8(4): e60845.
doi: 10.1371/journal.pone.0060845
pubmed: 23585856
pmcid: 3622008
Goka EA, Vallely PJ, Mutton KJ, Klapper PE. Single, dual and multiple respiratory virus infections and risk of hospitalization and mortality. Epidemiol Infect. 2015;143(1):37–47.
doi: 10.1017/S0950268814000302
pubmed: 24568719
John KJ, Nayar J, Mishra AK, Selvaraj V, Khan MS, Lal A. In-hospital clinical complications of COVID-19: a brief overview. Future Virol. 2021;16(11):717–23.
doi: 10.2217/fvl-2021-0200
Farias LdPGd, Strabelli DG, Fonseca EKUN, Loureiro BMC, Nomura CH, Sawamura MVY. Thoracic tomographic manifestations in symptomatic respiratory patients with COVID-19. Radiol Bras. 2020;53(4):255.
doi: 10.1590/0100-3984.2020.0030
pubmed: 32904780
pmcid: 7458567
Dadashi M, Khaleghnejad S, Abedi Elkhichi P, Goudarzi M, Goudarzi H, Taghavi A, et al. COVID-19 and influenza co-infection: a systematic review and meta-analysis. Front Med. 2021;25(8):971.
Al Sulaiman K, Korayem GB, Altebainawi AF, Al Harbi S, Alissa A, Alharthi A, et al. Evaluation of inhaled nitric oxide (iNO) treatment for moderate-to-severe ARDS in critically ill patients with COVID-19: a multicenter cohort study. Crit Care. 2022;26(1):304.
doi: 10.1186/s13054-022-04158-y
pubmed: 36192801
pmcid: 9527729